Chelsea Therapeutics, Inc. Joins With Advocates, Patients and Experts to Raise Awareness of Neurogenic Orthostatic Hypotension (NOH)

CHARLOTTE, N.C., Jan. 26, 2012 (GLOBE NEWSWIRE) -- Patients with Parkinson's disease, multiple system atrophy (MSA) and other neurological disorders can be greatly affected by the symptoms of their disease such as neurogenic orthostatic hypotension (NOH) that result from autonomic dysfunction. To give a voice to patients and their family caregivers who are impacted by the symptoms of NOH, Chelsea Therapeutics (Nasdaq:CHTP) announced today the formation of a partnership with leading medical and patient experts called the Alliance for NOH Awareness and the launch of an educational web site, www.SignsofNOH.com.